Literature DB >> 25871963

Protein kinase A defects and cortisol-producing adrenal tumors.

Mihail Zilbermint1, Constantine A Stratakis.   

Abstract

PURPOSE OF REVIEW: Cushing syndrome caused by cortisol-producing adrenal adenomas is a rare condition, associated with high morbidity due to weight gain, diabetes mellitus, osteoporosis, hypertension, muscle weakness, mood disturbance and others. The first gene to be identified as causative of Cushing syndrome was PRKAR1A. We present an update on protein kinase A (PKA) defects and Cushing syndrome. RECENT
FINDINGS: The cyclic AMP-dependent PKA catalytic subunit alpha (PRKACA) hotspot point mutation (c.617A > C [p.Leu206Arg]), leading to an increase of basal PKA activity, and formation of cortisol-producing adenoma has been frequently shown to cause the most common form of adrenocorticotropic hormone-independent Cushing syndrome.
SUMMARY: Somatic PRKACA mutations have been found in up to 50% of patients with adrenal adenomas. Germline PRKACA amplification was also seen in bilateral adrenal hyperplasias. PRKACA activation was associated with higher cortisol levels, smaller tumor size and overt Cushing syndrome. This breakthrough is expected to improve our understanding of how PKA defects lead to Cushing syndrome and may spearhead the development of new, molecularly designed therapies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25871963      PMCID: PMC4560837          DOI: 10.1097/MED.0000000000000149

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  46 in total

Review 1.  Genetics of adrenal diseases in 2014: Genetics improves understanding of adrenocortical tumours.

Authors:  Xavier Bertagna
Journal:  Nat Rev Endocrinol       Date:  2014-12-16       Impact factor: 43.330

2.  PDE 2013, Paris, France: another exciting workshop for cyclic AMP, protein kinase A, and phosphodiesterases.

Authors:  C A Stratakis; J Bertherat
Journal:  Horm Metab Res       Date:  2014-11-14       Impact factor: 2.936

3.  Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Authors:  L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

4.  Germline PRKACA amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic phenotypes.

Authors:  J Aidan Carney; Charalampos Lyssikatos; Maya B Lodish; Constantine A Stratakis
Journal:  Hum Pathol       Date:  2014-10-02       Impact factor: 3.466

5.  Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex.

Authors:  L S Kirschner; F Sandrini; J Monbo; J P Lin; J A Carney; C A Stratakis
Journal:  Hum Mol Genet       Date:  2000-12-12       Impact factor: 6.150

Review 6.  Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation.

Authors:  C A Stratakis; L S Kirschner; J A Carney
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

Review 7.  Protein kinase A alterations in adrenocortical tumors.

Authors:  S Espiard; B Ragazzon; J Bertherat
Journal:  Horm Metab Res       Date:  2014-08-08       Impact factor: 2.936

8.  Cyclic adenosine 3'-5'-monophosphate (cAMP) exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac).

Authors:  E Vitali; E Peverelli; E Giardino; M Locatelli; G B Lasio; P Beck-Peccoz; A Spada; A G Lania; G Mantovani
Journal:  Mol Cell Endocrinol       Date:  2013-12-25       Impact factor: 4.102

9.  Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma.

Authors:  Ulf Elbelt; Alessia Trovato; Michael Kloth; Enno Gentz; Reinhard Finke; Joachim Spranger; David Galas; Susanne Weber; Cristina Wolf; Katharina König; Wiebke Arlt; Reinhard Büttner; Patrick May; Bruno Allolio; Jochen G Schneider
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

10.  PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.

Authors:  S E Moody; A C Schinzel; S Singh; F Izzo; M R Strickland; L Luo; S R Thomas; J S Boehm; S Y Kim; Z C Wang; W C Hahn
Journal:  Oncogene       Date:  2014-06-09       Impact factor: 9.867

View more
  6 in total

Review 1.  Diagnosis and Clinical Genetics of Cushing Syndrome in Pediatrics.

Authors:  Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2016-06       Impact factor: 4.741

Review 2.  Cushing's Syndrome in Pediatrics: An Update.

Authors:  Maya B Lodish; Margaret F Keil; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

3.  Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling.

Authors:  Verena A Bachmann; Johanna E Mayrhofer; Ronit Ilouz; Philipp Tschaikner; Philipp Raffeiner; Ruth Röck; Mathieu Courcelles; Federico Apelt; Tsan-Wen Lu; George S Baillie; Pierre Thibault; Pia Aanstad; Ulrich Stelzl; Susan S Taylor; Eduard Stefan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-28       Impact factor: 11.205

Review 4.  β-catenin in adrenal zonation and disease.

Authors:  Donald W Little; Typhanie Dumontet; Christopher R LaPensee; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2020-12-16       Impact factor: 4.102

Review 5.  Adrenal hyperplasias in childhood: An update.

Authors:  Georgia Pitsava; Constantine A Stratakis
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-03       Impact factor: 6.055

6.  Impact of kinase activating and inactivating patient mutations on binary PKA interactions.

Authors:  Ruth Röck; Johanna E Mayrhofer; Verena Bachmann; Eduard Stefan
Journal:  Front Pharmacol       Date:  2015-08-18       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.